EDINBURGH, Scotland, Aug. 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the closing of its previously announced public offering of 2,000,000 shares of its American Depository Shares ("ADSs")(or pre-funded warrants in lieu thereof), together with Series G warrants ("Series G Warrants") to purchase up to 2,000 ...

Core Viewpoint - TC BioPharm is experiencing a decline in stock price following the announcement of a registered direct offering of its shares, which is expected to dilute existing shareholders' stakes [1][3]. Group 1: Offering Details - TC BioPharm is selling 2 million American Depository Shares (ADS) at a price of $1 per share, anticipating gross proceeds of $2 million from this offering [1][2]. - The company is also offering Series G warrants for 2 million shares to a single investor, with an exercise price of £0.78 per share [2]. Group 2: Use of Proceeds - The funds raised from the offering will be allocated to support clinical trials focused on relapse/refractory Acute Myeloid Leukemia, as well as for operating expenses and working capital [2]. Group 3: Market Reaction - Following the announcement, TCBP stock has dropped by 45.8%, with approximately 24,000 shares traded, which is about double its daily average [4]. - The offering price of $1 represents a significant discount compared to the previous closing price of $3.65 per share, contributing to the stock's decline [3].

EDINBURGH, Scotland, Aug. 13, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into definitive agreement for the purchase and sale of 2,000,000 shares of its American Depository Shares and Pre-Funded Warrants at an offering price of $1 per share in a registered direct offering and an additional 2,000 ...

EDINBURGH, Scotland, July 22, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that on July 16, the sixth patient in ACHIEVE (UK) was treated. This is the first patient treated with a higher dose of TCB-008 post the amendment approved by the MHRA on Feb 22, 2024. Interim data review is not reliant on the completion ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from _____________ to _____________ Commission File No. 001-41231 TC BIOPHARM (HOLDINGS) PLC (Exact Name of Registrant as Specified in Its Charter) | Scotland | N/A | | --- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transaction period from _____________ to _____________ Commission File No. 001-41231 TC BIOPHARM (HOLDINGS) PLC (Exact Name of Registrant as Specified in Its Charter) | Scotland | N/A | | --- | --- ...

The accompanying notes form an integral part of these unaudited condensed consolidated interim financial statements. 2 Exhibit 99.1 INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page | Unaudited Condensed Consolidated Statements of Income and Total Comprehensive Income for the Six Months Ended June | | | --- | --- | | 30, 2023 and 2022 | 2 | | Unaudited Condensed Consolidated Statements of Financial Position as at June 30, 2023 and December 31, 2022 | 3 | | Unaudited Condensed Conso ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR For the transition period from _______________________ to ______________________________ Commission File Number 001-41231 TC BIOPHARM (HOLDINGS) PLC (Exact name of Registrant as specified in its c ...